Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2026-10-18
Target enrollment:
Participant gender:
Summary
In this study, participants with locally advanced rectal cancer patients will be treated
according to MMR/MSI status. There will be two cohorts in this study: Cohort A and Cohort B.
For Cohort A, dMMR or MSI-H patients will receive neoadjuvant Pd1 antibody Sintilimab and
surgery or watch and wait, followed by adjuvant treatment. For Cohort B, pMMR/MSS/MSI-L
patients will be randomized to receive neoadjuvant chemoradiotherapy ± Pd1 antibody
Sintilimab， followed by surgery or watch and wait, and adjuvant treatment.